Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 15/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165633 | 0.90 | ADRB3 (0.84) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074042 | 0.90 | ADRB3 (0.84) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074029 | 0.90 | ADRB3 (0.84) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6075463 | 0.90 | ADRB3 (0.84) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074115 | 0.89 | ADRB3 (0.87) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074102 | 0.89 | ADRB3 (0.87) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074276 | 0.87 | ADRB3 (0.83) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074267 | 0.87 | ADRB3 (0.83) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074746 | 0.86 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6074739 | 0.86 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885ADRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.